Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPlastic/Reconstructive SurgeryAetna Breast Implant Removal Coverage Update | Ope…
    Ask Trek AI about this page
    CurrentAetnaPolicy 0142

    Breast Implant Removal

    Customize your policy alerts

    Sign up for Aetna Policy 0142 alerts

    Get alerted when Policy 0142 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical coverage policy describing when removal of breast implants (with capsulectomy or capsulotomy as applicable) is considered medically necessary, cosmetic, limited, or not medically necessary for Aetna members.

    Policy Summary
    PayerAetna
    PolicyBreast Implant Removal
    Policy CodePolicy 0142
    Change TypeNo material clinical or coverage changes
    Effective DateJul 11, 1996
    Last ReviewMar 28, 2023
    Next Review DateFeb 8, 2024
    Key ActionTry conservative treatments (e.g., antibiotics, oral/topical corticosteroids) for cutaneous hypersensitivity-like reactions before considering implant removal.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    10medical necessity indications listed
    19325-19371example code groups referenced
    9-13median implant-to-ALCL (years)
    154%fat grafting thickness increase
    22.2%complication rate (fat grafting)

    Coverage Criteria for Breast Implant Removal

    Medical Necessity — Primary Indications

    Covered when ANY of the following are met for members (cosmetic augmentation, reconstruction after medically necessary mastectomy, or augmentation for gender dysphoria):

    Primary indications (any): 1. Breast cancer in the implanted breast or remnant, or in the contralateral breast where implant removal is necessary to excise the breast cancer; OR 2. Breast implant-associated anaplastic large cell lymphoma; OR 3. Extrusion of implant through skin; OR 4. Implants complicated by recurrent infections; OR 5. Implants with Baker Class IV contracture associated with severe pain; OR 6. Implants with severe contracture that interferes with mammography; OR 7. Intra- or extra-capsular rupture of silicone gel-filled implants; OR 8. Members who exhibit cutaneous hypersensitivity-like reactions associated with breast implants and who have failed conventional treatments (e.g., antibiotics, oral and topical corticosteroids); OR 9. Persons with textured implants that have been withdrawn from the market at the request of the FDA (Allergan Biocell); OR 10. Persons with textured breast implants who exhibit persistent symptoms such as pain, lumps, swelling, or asymmetry after the surgical incision has fully healed.

    From policy medical necessity list.

    Medical Necessity — Reconstruction-specific Indications

    Additional medically necessary indications when reconstruction followed a medically necessary mastectomy or augmentation for gender dysphoria:

    Reconstruction-specific indications: 1. Baker Class III contracture (when reconstruction followed a medically necessary mastectomy); OR 2. Extra-capsular rupture of saline implant if the rupture compromises the cosmetic outcome of the implant.

    These are additional criteria specific to reconstructed breasts. Photographic documentation of contracture may be required; if unilateral criteria are met, bilateral removal when performed at the same time is considered medically necessary.

    Cosmetic

    Cosmetic stance:

    Autologous fat grafting (lipoaugmentation) following breast implant removal is considered cosmetic when the implant was originally placed for cosmetic indications.

    Re-insertion of new breast implants after removal for medical indications is considered cosmetic if the original implant was cosmetic.

    Removal of a ruptured saline-filled breast implant is not considered medically necessary when the implant was originally placed for cosmetic augmentation. The policy explicitly states that Aetna considers removal of ruptured saline-filled breast implants not medically necessary for members who previously underwent cosmetic breast augmentation mammoplasty. Providers should therefore expect such requests to be denied unless another listed medical necessity criterion applies.

    For reconstructed breasts (implantation following a medically necessary mastectomy or augmentation for gender dysphoria), different reconstruction-specific indications apply (e.g., Baker Class III contracture or extra-capsular saline rupture that compromises cosmetic outcome). Photographic documentation of contracture may be required when evaluating requests in those reconstructed cases.

    IgG antibody testing in connection with silicone breast implants is not considered medically necessary. The policy specifies that development of IgG antibodies is neither specific to silicone implants nor indicative of autoimmune disorders, and therefore Aetna does not consider IgG testing for this purpose medically necessary.

    Separately, removal of silicone implants for autoimmune disease is not considered medically necessary unless the member meets at least one of the policy's listed selection criteria (for example, rupture of a silicone gel–filled implant or another primary medical indication).

    Coding and Related Clinical Notes

    Covered CPT Codes (if selection criteria met)CPTCovered
    19325Mammoplasty, augmentation; with prosthetic implant.
    19328Removal of intact mammary implant.
    19330Removal of mammary implant material.
    19340Immediate insertion of breast prosthesis following mastopexy, mastectomy or in reconstruction.
    19342Delayed insertion of breast prosthesis following mastopexy, mastectomy or in reconstruction.
    19370Open periprosthetic capsulotomy, breast.
    19371Periprosthetic capsulectomy, breast.
    CPT Codes not covered for indications listed in the CPBCPTNot Covered
    15769Grafting of autologous soft tissue, other, harvested by direct excision (eg, fat, dermis, fascia).
    15771Grafting of autologous fat harvested by liposuction technique to trunk, breasts, scalp, arms, and/or legs; 50 cc or less injectate.
    15772each additional 50 cc injectate, or part thereof (List separately in addition to code for primary procedure).
    15773Grafting of autologous fat harvested by liposuction technique to face, eyelids, mouth, neck, ears, orbits, genitalia, hands, and/or feet; 25 cc or less injectate.
    15774each additional 25 cc injectate, or part thereof (List separately in addition to code for primary procedure).
    Other related CPT CodesCPT
    19120-19126Breast, excision of cyst, fibroadenoma, or other benign or malignant tumor, aberrant breast tissue, duct lesion, nipple or areolar lesion (except 19300), open, male or female, one or more lesions.
    19316-19380Breast, repair and/or reconstruction procedures.
    HCPCS CodesHCPCS
    L8020-L8039Breast prostheses.
    L8600Implantable breast prosthesis, silicone or equal.
    ICD-10 Codes (covered if selection criteria met)ICD-10Covered
    C50.011-C50.929Malignant neoplasm of breast.
    C84.60-C84.69Anaplastic large cell lymphoma, ALK-positive.
    C84.70-C84.79Anaplastic large cell lymphoma, ALK-negative.
    F64.0-F64.9Gender identity disorders.
    N63.0-N63.42Unspecified lump in breast.
    N64.4Mastodynia.
    R52Pain, unspecified.
    T85.41x+-T85.49x+Mechanical complication of breast prosthesis and implant.
    T85.79x+Infection and inflammatory reaction due to other internal prosthetic devices, implants, or grafts.
    Typical time from implant to BIA-ALCL
    Typical interval (median)Median time from implant placement to presentation with BIA-ALCL reported as approximately 9–13 years (median 9 years in Laurent et al; average 13.3 years in Locke & Lofts).
    Reported rangesReported ranges in cited series include 9 years (median) and 10–16 years (range) in individual cohorts.
    Clinical implicationBIA-ALCL typically presents late (years after implantation); evaluate late seroma, persistent swelling, pain, lumps, or asymmetry for possible BIA-ALCL.

    Provider Actions and Authorization Guidance

    Note

    Codes contingent on meeting selection criteria

    Coverage of the listed CPT, HCPCS and ICD-10 codes is contingent on meeting the policy's selection criteria; the policy lists specific codes that are covered only if medical necessity criteria are satisfied.

    • Covered CPT codes if selection criteria met: 19325, 19328, 19330, 19340, 19342, 19370, 19371.
    • CPT codes noted as not covered for indications in this CPB: 15769, 15771, 15772, 15773, 15774.
    • Other related CPT ranges: 19120-19126; 19316-19380.
    • HCPCS: L8020-L8039; L8600.
    • ICD-10 codes covered if selection criteria met include C50.011-C50.929, C84.60-C84.69, C84.70-C84.79, F64.0-F64.9, N63.0-N63.42, N64.4, R52, T85.41x+-T85.49x+, T85.79x+.
    Prior Authorization

    Prior authorization: consult full policy/benefit

    The excerpt does not specify code-level prior authorization requirements; providers should check the member's benefit plan or complete policy for any prior authorization rules that apply to these procedures and codes.

    Background and Clinical Context

    Silicone implant rupture may be classified as intracapsular or extracapsular. An intracapsular rupture denotes silicone gel contained within the fibrous capsule surrounding the implant, whereas an extracapsular rupture involves silicone gel extruded beyond the capsule, which may induce granulomatous reactions or migrate to regional lymph nodes.

    Clinically, extracapsular rupture is more likely to produce observable symptoms or changes and is therefore regarded as an indication for explantation when it leads to clinical problems. The policy reflects this distinction by listing intra- or extracapsular rupture of silicone gel–filled implants among the primary indications for medically necessary removal, while noting reconstruction-specific allowance for extra-capsular saline rupture when it compromises cosmetic outcome.

    Definitions and Classifications

    Intracapsular rupture definition
    DefinitionIntracapsular rupture: silicone gel is extruded but contained within the fibrous capsule surrounding the implant.
    Health consequencesHealth consequences are uncertain because silicone remains within the capsule; intact implants can also 'bleed' microscopic silicone particles contained by the capsule.
    Clinical courseAn intracapsular rupture can evolve to extracapsular rupture; the FDA indicates ruptured implants (intra- or extracapsular) should be explanted.
    Extracapsular rupture definition
    DefinitionExtracapsular rupture: silicone gel is extruded beyond the fibrous capsule surrounding the implant.
    Clinical signsOften associated with change in breast size and consistency and can usually be identified on mammography or other imaging studies.
    Policy Summary
    PayerAetna
    PolicyBreast Implant Removal
    Policy CodePolicy 0142
    Change TypeNo material clinical or coverage changes
    Effective DateJul 11, 1996
    Last ReviewMar 28, 2023
    Next Review DateFeb 8, 2024
    Key ActionTry conservative treatments (e.g., antibiotics, oral/topical corticosteroids) for cutaneous hypersensitivity-like reactions before considering implant removal.
    SourceLink
    On This Page
    Coverage Criteria for Breast Implant RemovalCoding and Related Clinical NotesProvider Actions and Authorization GuidanceBackground and Clinical ContextDefinitions and Classifications
    • Consult the complete policy and the member's benefit plan to determine whether prior authorization is required for any CPT/HCPCS/ICD-10 codes listed in this policy.
    Step Therapy

    Try conservative treatments before explantation for hypersensitivity-like reactions

    Conservative therapy should be attempted for cutaneous hypersensitivity–like reactions associated with breast implants before considering explantation; examples include antibiotics, oral corticosteroids, and topical corticosteroids.

    • Explantation may be considered only after failure of conventional treatments such as antibiotics, oral corticosteroids, and topical corticosteroids.
    Step Therapy

    Infection pathway: trial antibiotics → salvage → explantation as indicated

    Management of infected implants may start with a trial of antibiotics for mild infections, proceed to surgical salvage when indicated, or result in explantation depending on severity and response; published evidence shows some mild infections respond to antibiotics alone while others require surgical intervention or removal.

    • In systematic review data, ~29% of patients with mild infection were treated exclusively with antibiotics, with ~81% success.
    • Surgical salvage was attempted in ~39% with ~85% success in retaining implants.
    • Explantation occurred in ~35% of cases; a minority later had re‑implantation.
    Documentation Required

    Document contracture photographically; bilateral removal allowed when unilateral criteria met

    Photographic documentation of capsular contracture may be required for medical review; if unilateral criteria for removal are met, removal of the contralateral implant at the same operative session is considered medically necessary.

    • Photographs may be requested to document Baker class contracture.
    • If criteria are met for one breast, bilateral removal with capsulectomy/capsulotomy at the same time is medically necessary.
    Note

    Policy metadata and review dates for administrative processing

    Reference the policy's administrative metadata (effective date 07/11/1996; last review 03/28/2023; next review 02/08/2024) when processing requests and appeals to ensure use of the current policy version.

    • Effective date: 07/11/1996.
    • Last review: 03/28/2023.
    • Next review: 02/08/2024.
    Denial Risk

    Denial risk: Baker Class III (non‑reconstruction) and certain removal indications

    Removal requests for Baker Class III contracture that do not follow a medically necessary mastectomy are subject to medical review and may be denied; implant removal for biopsy of a breast mass not proven malignant or removal for mastectomy/lumpectomy that can be done with the implant in place are also subject to medical review and may be denied.

    • Baker Class III contracture requests not following a medically necessary mastectomy are reviewable and may be denied.
    • Implant removal for biopsy of a breast mass not proven cancerous may be denied.
    • Requests to remove an implant when the mastectomy or lumpectomy could be performed with the implant in place may be denied.
    Note

    Administrative note: policy history present; prior authorization details not specified here

    Administrative note: this policy excerpt shows policy status and review history but does not state explicit prior authorization requirements; verify code-level authorization rules with the full policy or the member's benefit plan.

    • Policy status available; absence of explicit prior authorization language in this excerpt.
    • Providers must confirm authorization requirements elsewhere as needed.
    Health consequences and managementExtracapsular silicone can induce granulomatous reaction and may migrate to axillary lymph nodes; explantation of these implants is clearly indicated.
    BIA-ALCL — definition and brief management note
    DefinitionBreast implant–associated anaplastic large cell lymphoma (BIA-ALCL): a rare, usually ALK‑negative T‑cell lymphoma occurring in association with breast implants; malignant cells are CD30‑positive and often confined to the capsule, seroma, or an adjacent mass.
    Typical presentationPatients commonly present with late seroma, swelling, pain, a palpable mass, or asymmetry; late seroma without infection should prompt aspiration and cytologic analysis.
    Initial managementFor capsule‑confined disease, implant removal with complete capsulectomy (total capsulectomy) is the preferred treatment; patients with a mass or extracapsular spread may require systemic therapy in addition to surgery and should be referred to a specialist and reported to the FDA.
    Baker Classification — capsular contracture scale I–IV
    Class IAugmented breast feels soft as a normal breast.
    Class IIAugmented breast is less soft and implant can be palpated, but is not visible.
    Class IIIAugmented breast is firm; implant is palpable and the implant (or distortion) is visible.
    Class IVAugmented breast is hard, painful, cold, tender, and distorted.